Article Text

PDF
Enteric-coated potassium: why are hydrosaluric-K and salupres still marketed?

Abstract

About 1964 enteric-coated potassium chloride preparations became recognised as a specific cause of small-bowel ulceration, leading to stricture or perforation. Since then almost all manufacturers of slow-release potassium chloride supplements have used other formulations, (e. g. embedding the drug in a wax-core, as in Slow-K) with which the risk is much less, though it must still be considered in patients who already have oesophageal or small-bowel obstruction. Two preparations containing enteric-coated potassium remain available, however, though Merck Sharp & Dohme, the manufacturer, tells us that they are not promoted. The preparations are Hydrosaluric-K (hydrochlorothiazide + potassium chloride) and Salupres (hydrochlorothiazide + reserpine + potassium chloride), and cases of small-bowel ulceration associated with the use of these tablets continue to be reported,1 2 despite the warning (mandatory since 1967 for all solid preparations of potassium salts), to ‘discontinue use if symptoms or signs of small-bowel ulceration develop’.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.